Brian D Gonzalez1, Sarah L Eisel2, Bo Qin3, Adana A M Llanos4, Josée Savard5,6, Aasha I Hoogland2, Heather Jim2, Yong Lin4, Kitaw Demissie7, Chi-Chen Hong8, Elisa V Bandera3,4. 1. Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CAN CONT, Tampa, FL, 33612, USA. Brian.Gonzalez@Moffitt.org. 2. Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CAN CONT, Tampa, FL, 33612, USA. 3. Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 4. Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA. 5. School of Psychology, Université Laval, Quebec, Canada. 6. CHU de Québec-Université Laval Research Center, Université Laval, Quebec, Canada. 7. Department of Epidemiology and Biostatistics, The State University of New York (SUNY) Downstate Health Sciences University School of Public Health, New York, NY, USA. 8. Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Abstract
PURPOSE: Sleep disturbance may be an overlooked modifiable risk factor for health disparities among African-American breast cancer survivors (AABCS). This study aimed to identify the prevalence of and risk factors for sleep disturbance in a cohort of AABCS. METHODS: The study was conducted among participants in the Women's Circle of Health Follow-up Study, a longitudinal study of breast cancer in 10 counties in New Jersey. Cases were identified shortly after diagnosis by the New Jersey State Cancer Registry. Self-reported sleep disturbance (Pittsburgh Sleep Quality Index) and other factors (e.g., socioeconomic status, menopausal status) were assessed at pre-diagnosis (n = 637), 10 months post-diagnosis (n = 261), and 24 months post-diagnosis (n = 632). Clinical data were obtained via medical record abstraction, and height and weight were measured by study staff. RESULTS: Most AABCS (57%) reported clinically significant sleep disturbance before diagnosis, and this rate remained largely unchanged at 10 months (53%) and 24 months post-diagnosis (61%). Average sleep disturbance scores indicated clinically significant disturbance at all three assessments (M range = 6.67-7.57). Most reported sleeping fewer than the recommended 7 hours per night at each assessment (range 57-65%). Risk factors for sleep disturbance were identified at each assessment, including pre-diagnosis (less education), 10 months post-diagnosis (lack of insurance, treatment with chemotherapy), and 24 months post-diagnosis (younger age, less education, lower income, obesity, and lymphedema). Treatment with endocrine therapy was a protective factor at 10 months post-diagnosis. CONCLUSION: Most AABCS report clinically significant sleep disturbance from before diagnosis through 24 months post-diagnosis. These rates appear indicate AABCS experience significant sleep-related disparities.
PURPOSE: Sleep disturbance may be an overlooked modifiable risk factor for health disparities among African-American breast cancer survivors (AABCS). This study aimed to identify the prevalence of and risk factors for sleep disturbance in a cohort of AABCS. METHODS: The study was conducted among participants in the Women's Circle of Health Follow-up Study, a longitudinal study of breast cancer in 10 counties in New Jersey. Cases were identified shortly after diagnosis by the New Jersey State Cancer Registry. Self-reported sleep disturbance (Pittsburgh Sleep Quality Index) and other factors (e.g., socioeconomic status, menopausal status) were assessed at pre-diagnosis (n = 637), 10 months post-diagnosis (n = 261), and 24 months post-diagnosis (n = 632). Clinical data were obtained via medical record abstraction, and height and weight were measured by study staff. RESULTS: Most AABCS (57%) reported clinically significant sleep disturbance before diagnosis, and this rate remained largely unchanged at 10 months (53%) and 24 months post-diagnosis (61%). Average sleep disturbance scores indicated clinically significant disturbance at all three assessments (M range = 6.67-7.57). Most reported sleeping fewer than the recommended 7 hours per night at each assessment (range 57-65%). Risk factors for sleep disturbance were identified at each assessment, including pre-diagnosis (less education), 10 months post-diagnosis (lack of insurance, treatment with chemotherapy), and 24 months post-diagnosis (younger age, less education, lower income, obesity, and lymphedema). Treatment with endocrine therapy was a protective factor at 10 months post-diagnosis. CONCLUSION: Most AABCS report clinically significant sleep disturbance from before diagnosis through 24 months post-diagnosis. These rates appear indicate AABCS experience significant sleep-related disparities.
Entities:
Keywords:
African-American or African-American cancer survivors; Breast neoplasms; Cancer; Oncology; Quality of life; Sleep; Survivorship
Authors: Michael A Grandner; Nirav P Patel; Philip R Gehrman; Michael L Perlis; Allan I Pack Journal: Sleep Med Rev Date: 2009-11-06 Impact factor: 11.609
Authors: Nathaniel F Watson; M Safwan Badr; Gregory Belenky; Donald L Bliwise; Orfeu M Buxton; Daniel Buysse; David F Dinges; James Gangwisch; Michael A Grandner; Clete Kushida; Raman K Malhotra; Jennifer L Martin; Sanjay R Patel; Stuart F Quan; Esra Tasali; Michael Twery; Janet B Croft; Elise Maher; Jerome A Barrett; Sherene M Thomas; Jonathan L Heald Journal: J Clin Sleep Med Date: 2015-06-15 Impact factor: 4.062
Authors: Elizabeth J Mezick; Karen A Matthews; Martica Hall; Patrick J Strollo; Daniel J Buysse; Thomas W Kamarck; Jane F Owens; Steven E Reis Journal: Psychosom Med Date: 2008-05 Impact factor: 4.312
Authors: Teletia R Taylor; Edward D Huntley; Kepher Makambi; Jennifer Sween; Lucile L Adams-Campbell; Wayne Frederick; Thomas A Mellman Journal: Psychooncology Date: 2011-06-05 Impact factor: 3.955
Authors: Elisa V Bandera; Urmila Chandran; Gary Zirpoli; Zhihong Gong; Susan E McCann; Chi-Chen Hong; Gregory Ciupak; Karen Pawlish; Christine B Ambrosone Journal: BMC Cancer Date: 2013-10-14 Impact factor: 4.430
Authors: Christine B Ambrosone; Gregory L Ciupak; Elisa V Bandera; Lina Jandorf; Dana H Bovbjerg; Gary Zirpoli; Karen Pawlish; James Godbold; Helena Furberg; Anne Fatone; Heiddis Valdimarsdottir; Song Yao; Yulin Li; Helena Hwang; Warren Davis; Michelle Roberts; Lara Sucheston; Kitaw Demissie; Kandace L Amend; Paul Tartter; James Reilly; Benjamin W Pace; Thomas Rohan; Joseph Sparano; George Raptis; Maria Castaldi; Alison Estabrook; Sheldon Feldman; Christina Weltz; Margaret Kemeny Journal: J Oncol Date: 2009-10-25 Impact factor: 4.375
Authors: Xi Luo; Qin Xie; Qiuling Shi; Yan Miao; Qingsong Yu; Hongfan Yu; Hong Yin; Xuefeng Leng; Yongtao Han; Hong Zhou Journal: Support Care Cancer Date: 2021-11-24 Impact factor: 3.603
Authors: Charlotte Grégoire; Nolwenn Marie; Corine Sombrun; Marie-Elisabeth Faymonville; Ilios Kotsou; Valérie van Nitsen; Sybille de Ribaucourt; Guy Jerusalem; Steven Laureys; Audrey Vanhaudenhuyse; Olivia Gosseries Journal: Front Psychol Date: 2022-02-10